LONDON, Nov. 3, 2016 /PRNewswire/ -- Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cancer radiotherapy, cumulative daily doses of radiation to the treatment field or target site on the body prevents normal skin to repopulate and weakens the skin integrity at and around the radiation field. Radiodermatitis may be acute or chronic and encompasses localized erythema, skin shedding (desquamation), hair loss (epilation), fibrosis, necrosis, and other similar conditions. Radiodermatitis affects a patient's quality of life, causes pain and discomfort, and hinders in the continuous treatment regimes. Radiodermatitis can also cause interruption in or cessation of treatment, depending on the severity of reaction.This report on the global radiodermatitis market analyzes the current and future prospects of the market. The report comprises an elaborate executive summary, including a market snapshot that provides overall information of various segments and sub-segments. The research is a combination of primary and secondary research. A detailed qualitative analysis of factors responsible for driving and restraining market growth and opportunities has been provided in the market overview section. Market revenue in terms of US$ Mn for the period between 2014 and 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all the segments, considering 2015 as the base year. Market related factors such as increasing preference for efficacious products, product innovation, and historical year-on-year growth have been taken into consideration while estimating the market size. Growth rates for each segment within the global radiodermatitis market have been determined after a thorough analysis of past trends, demographics, future trends, technological developments, clinical trials, and regulatory requirements. These factors would help the market players to take strategic decisions in order to strengthen their positions and expand their share in the global market.Based on product type, the global radiodermatitis market has been segmented into topical, oral medication and dressings. The market has been further studied from the point of view of major type of topical applicants, oral medication, and dressings used for radiation dermatitis treatment. The topical segment is sub-segmented into topical corticosteroids, hydrophilic creams, and others (topical antibiotics). The oral medication segment comprises oral corticosteroids and others (oral analgesic and antibiotics). Hydrogel, hydrocolloid, no sting barrier film, honey impregnated gauze, silicone coated dressing, and others (silver leaf dressings, GM-CSF gauze, etc.) form the major sub-segments of the dressings segment. Consumer buying behavior is inclined toward dressings and topical products due to ease of use and suitability in the treatment of radiodermatitis symptoms.The major distribution channels for sale of radiation dermatitis products include hospital pharmacy, retail pharmacy store, and online store. Online store is set to witness rapid growth due to the various benefits rendered to a radiodermatitis affected patient unwilling to visit outdoor medical stores. These benefits include easy shipping, huge discounts, and convenience of purchasing from any location.Geographically, the global radiodermatitis market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In addition, the regions have been further segmented by major countries. These include the U.S., Canada, the U.K., Germany, China, Japan, Brazil, Mexico, the UAE, and South Africa. The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the radiodermatitis market. The report also profiles major players in the radiodermatitis market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Key companies profiled in the report include 3M Health Care, BMG Pharma, Molnlycke Health Care, Smith & Nephew plc., Derma Sciences, Inc., Alliqua Biomedical, Acelity LP, Intermed Pharmaceuticals, and Stratpharma AG.The global radiodermatitis market has been segmented as follows:Global Radiodermatitis Market, by ProductTopicalCorticosteroidsHydrophilic CreamsOthers (topical antibiotics)Oral MedicationCorticosteroidsOther (oral analgesics, antibiotics, etc.)DressingsHydrogelHydrocolloidNo Sting Barrier FilmHoney Impregnated GauzeSilicone Coated DressingOthers (GM-CSF gauze, silver leaf dressing, etc.)Global Radiodermatitis Market, by Distribution ChannelHospital PharmacyRetail Pharmacy StoreOnline StoreGlobal Radiodermatitis Market, by GeographyNorth AmericaU.S.CanadaAsia PacificChinaJapanRest of APACEuropeU.K.GermanyRest of EuropeLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & AfricaUAESouth AfricaRest of Middle East & AfricaDownload the full report: https://www.reportbuyer.com/product/4268679/About ReportbuyerReportbuyer is a leading industry intelligence solution that provides all market research reports from top publishershttp://www.reportbuyer.comFor more information: Sarah Smith
Research Advisor at Reportbuyer.com Email: [email protected]
Tel: +44 208 816 85 48 Website: www.reportbuyer.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/radiodermatitis-market---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300357419.html
SOURCE ReportBuyer
